DILH
ACAD icon

Dai-ichi Life Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Dai-ichi Life Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-34,392
Closed -$1.09M – 8
2016
Q3 		$1.09M Sell
34,392
-1,714
-5% -$58.1K 0.03% 396
2016
Q2 		$1.17M Buy
+36,106
New +$1.21M 0.04% 384

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Dai-ichi Life Holdings's ACAD Position: Q4 2016 in Review

Dai-ichi Life Holdings sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 34,392 shares — an estimated $1.09M sold.

Dai-ichi Life Holdings first reported a position in ACAD in Q2 2016 and held it in 2 quarters. The position peaked at $1.17M in Q2 2016. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • Dai-ichi Life Holdings reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Dai-ichi Life Holdings sold 34,392 Acadia Pharmaceuticals shares in Q4 2016, an estimated $1.09M.
  • Dai-ichi Life Holdings first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Dai-ichi Life Holdings's Acadia Pharmaceuticals position peaked at $1.17M in Q2 2016.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Dai-ichi Life Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.